On July 24, 2023, Acasti Pharma Inc. regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market following a one-for-six reverse split of its common shares effective on July 10, 2023.
AI Assistant
GRACE THERAPEUTICS INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.